Search

Your search keyword '"Xiao, Junjuan"' showing total 16 results
Start Over Author "Xiao, Junjuan"
16 results on '"Xiao, Junjuan"'

3. Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer

Author

Cui, Yu, primary, Han, Xinyue, additional, Liu, Hongtao, additional, Xie, Qi, additional, Guan, Yaping, additional, Yin, Beibei, additional, Xiao, Junjuan, additional, Feng, Dongfeng, additional, Wang, Xuan, additional, Li, Junwei, additional, Chen, Jinghua, additional, Liu, Xiaolin, additional, Li, Xingyu, additional, Nie, Weiwei, additional, Ma, Lin, additional, Liu, Hairong, additional, Liang, Jing, additional, Li, Yan, additional, Wang, Baocheng, additional, and Wang, Jun, additional

Published
2023
Full Text
View/download PDF

5. Adjuvant therapy fails to show survival benefit for patients with spindle cell carcinoma: Evidence from the surveillance, epidemiology, and end results database

Author

Li, Ting, Xie, Qi, Li, Junwei, Li, Zhen, Xiao, Junjuan, Liu, Mingguo, Wang, Jun, Li, Yan, Tang, Fang, and Liang, Jing

Subjects
Drug therapy, Usage, Patient outcomes, Radiotherapy -- Usage -- Patient outcomes, Squamous cell carcinoma -- Drug therapy -- Patient outcomes, Rare diseases -- Drug therapy -- Patient outcomes, Adjuvant chemotherapy -- Usage -- Patient outcomes, Cancer -- Adjuvant treatment
Published
2021

7. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review

Author

Yin, Beibei, Xiao, Junjuan, Li, Junwei, Liu, Xiaohong, and Wang, Jun

Subjects
Drug therapy, Diagnosis, Usage, Complications and side effects, Risk factors, Dosage and administration, Pneumonia -- Risk factors -- Diagnosis, Immunotherapy -- Usage -- Complications and side effects, Pembrolizumab -- Dosage and administration -- Complications and side effects, Non-small cell lung cancer -- Drug therapy, Bacterial pneumonia -- Risk factors -- Diagnosis, Lung cancer, Non-small cell -- Drug therapy
Published
2020

16. Stathmin is a potential molecular marker and target for the treatment of gastric cancer.

Author

Liu X, Liu H, Liang J, Yin B, Xiao J, Li J, Feng D, and Li Y

Abstract

Objective: This study is to investigate the expression levels of stathmin in tissues of gastric cancer, and evaluate the therapeutic effects of stathmin antisense oligodeoxynucleotide (ASODN) and/or docetaxel in human gastric cancer cells., Methods: Immunohistochemistry was performed to detect the expression levels of stathmin in gastric cancer and adjacent tissues. Stathmin ASODN was transfected into gastric cancer SGC 7901 cell lines. The cell proliferation was assessed with the MTT assay, and the inhibitory rates were calculated. RT-PCR and Western blot analysis were performed to detect the mRNA and protein expression levels of stathmin, respectively. The synergistic effects of stathmin ASODN and docetaxel were evaluated. The efficacy and clinical benefit rates of the treatment of docetaxel combined with stathmin evaluation were investigated and compared., Results: Our results showed that the expression of stathmin was elevated in gastric cancer tissues, indicating a possible association between the stathmin expression and the disease occurrence. The MTT assay and tumor growth experiment revealed that stathmin ASODN significantly inhibited the proliferation of gastric cancer cells, both in vitro and in vivo. Furthermore, stathmin ASDON enhanced the inhibitory effects of docetaxel on the proliferation of gastric cancer cells, indicating a synergistic effect for the combination treatment. Importantly, docetaxel treatment was more effective for stathmin-negative gastric cancer patients, compared with stathmin-positive patients., Conclusion: Stathmin expression provides evidence for the treatment planning for gastric cancers. Stathmin might be a potential molecular marker and target for the treatment of gastric cancer.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results